"Antibodies, Viral" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Immunoglobulins produced in response to VIRAL ANTIGENS.
Descriptor ID |
D000914
|
MeSH Number(s) |
D12.776.124.486.485.114.254 D12.776.124.790.651.114.254 D12.776.377.715.548.114.254
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Viral".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Viral".
This graph shows the total number of publications written about "Antibodies, Viral" by people in this website by year, and whether "Antibodies, Viral" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 1 | 0 | 1 |
1996 | 1 | 0 | 1 |
1997 | 0 | 1 | 1 |
2000 | 0 | 1 | 1 |
2003 | 1 | 0 | 1 |
2004 | 1 | 0 | 1 |
2005 | 0 | 1 | 1 |
2006 | 3 | 1 | 4 |
2007 | 1 | 0 | 1 |
2008 | 0 | 2 | 2 |
2010 | 0 | 1 | 1 |
2011 | 1 | 2 | 3 |
2012 | 0 | 2 | 2 |
2013 | 1 | 1 | 2 |
2015 | 1 | 0 | 1 |
2016 | 1 | 1 | 2 |
2017 | 1 | 2 | 3 |
2020 | 1 | 2 | 3 |
2021 | 1 | 0 | 1 |
2022 | 0 | 4 | 4 |
2023 | 0 | 3 | 3 |
2024 | 6 | 2 | 8 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antibodies, Viral" by people in Profiles.
-
Risk reduction in SARS-CoV-2 infection and reinfection conferred by humoral antibody levels among essential workers during Omicron predominance. PLoS One. 2024; 19(12):e0306953.
-
Molecular features of the serological IgG repertoire elicited by egg-based, cell-based, or recombinant haemagglutinin-based seasonal influenza vaccines: a comparative, prospective, observational cohort study. Lancet Microbe. 2025 Feb; 6(2):100935.
-
Immunogenicity and Safety of Extended-Interval 2-Dose Regimens of 9vHPV Vaccine. Pediatrics. 2024 Aug 01; 154(2).
-
Antibody response to sequential vaccination with cell culture, recombinant, or egg-based influenza vaccines among U.S. adults. Hum Vaccin Immunother. 2024 Dec 31; 20(1):2370087.
-
Relative contribution of COVID-19 vaccination and SARS-CoV-2 infection to population-level seroprevalence of SARS-CoV-2 spike antibodies in a large integrated health system. PLoS One. 2024; 19(6):e0303303.
-
Assessing the association between antibody status and symptoms of long COVID: A multisite study. PLoS One. 2024; 19(6):e0304262.
-
Ipsilateral and contralateral coadministration of influenza and COVID-19 vaccines produce similar antibody responses. EBioMedicine. 2024 May; 103:105103.
-
Redirecting antibody responses from egg-adapted epitopes following repeat vaccination with recombinant or cell culture-based versus egg-based influenza vaccines. Nat Commun. 2024 Jan 04; 15(1):254.
-
Immunogenicity and safety of varying dosages of a fifth-wave influenza A/H7N9 inactivated vaccine given with and without AS03 adjuvant in healthy adults. Vaccine. 2024 Jan 12; 42(2):295-309.
-
Immunogenicity and Safety of a Third COVID-19 BNT162b2 mRNA Vaccine Dose in 5- to 11-Year Olds. J Pediatric Infect Dis Soc. 2023 Apr 28; 12(4):234-238.